Results 21 to 30 of about 144,436 (251)

Peripheral CD4 memory T cells predict the efficacy of immune checkpoint inhibitor therapy in patients with non-small cell lung cancer

Scientific Reports, 2023
Immune checkpoint inhibitors have significantly improved the prognosis in patients with non-small cell lung cancer, compared with cytotoxic agents.
Minehiko Inomata, Masahiro Matsumoto, Naoki Takata, Kana Hayashi, Zenta Seto, Takahiro Hirai, Kotaro Tokui, Chihiro Taka, Seisuke Okazawa, Kenta Kambara, Shingo Imanishi, Toshiro Miwa, Ryuji Hayashi, Shoko Matsui, Kazuyuki Tobe   +14 more
doaj   +1 more source

Gene signature reveals decreased SOX10-dependent transcripts in malignant cells from immune checkpoint inhibitor-resistant cutaneous melanomas

iScience, 2023
Summary: Evidence is mounting for cross-resistance between immune checkpoint and targeted kinase inhibitor therapies in cutaneous melanoma patients. Since the loss of the transcription factor, SOX10, causes tolerance to MAPK pathway inhibitors, we used ...
Timothy J. Purwin, Signe Caksa, Ahmet Sacan, Claudia Capparelli, Andrew E. Aplin   +4 more
doaj   +1 more source

The effects of B cell depletion on immune related adverse events associated with immune checkpoint inhibition

Experimental Hematology & Oncology, 2020
This letter describes the potential effect of B cell depletion on immune related adverse events associated with immune checkpoint inhibition. B cell depleting agents such as rituximab reduce B cell to plasma cell differentiation and antibody production ...
Rasmus Strøm Risbjerg, Mie Vennize Hansen, Anne Sofie Sørensen, Tue Wenzel Kragstrup   +3 more
doaj   +1 more source

Immune Checkpoint Inhibitors in Cancer Therapy

Current Oncology, 2022
The discovery of immune checkpoint proteins such as PD-1/PDL-1 and CTLA-4 represents a significant breakthrough in the field of cancer immunotherapy. Therefore, humanized monoclonal antibodies, targeting these immune checkpoint proteins have been utilized successfully in patients with metastatic melanoma, renal cell carcinoma, head and neck cancers and
Yavar Shiravand, Faezeh Khodadadi, Seyyed Mohammad Amin Kashani, Seyed Reza Hosseini-Fard, Shadi Hosseini, Habib Sadeghirad, Rahul Ladwa, Ken O’Byrne, Arutha Kulasinghe   +8 more
openaire   +6 more sources

Chronic immune checkpoint inhibitor pneumonitis

Journal for ImmunoTherapy of Cancer, 2020
Background Pneumonitis from immune checkpoint inhibitors (ICI) is a potentially fatal immune-related adverse event (irAE) from antiprogrammed death 1/programmed death ligand 1 immunotherapy. Most cases of ICI pneumonitis improve or resolve with 4–6 weeks
Julie R Brahmer, Patrick M Forde, Evan J Lipson, Jarushka Naidoo, Joanne Riemer, Daphne Wang, Janis M Taube, Cheng Ting Lin, Peter B Illei, Tricia R Cottrell, Lonny B Yarmus, K Ranh Voong, David Feller-Kopman, Hans Lee, Sonye K Danoff, Franco R D'Alessio, Karthik Suresh   +16 more
doaj   +1 more source

Immune Checkpoint Inhibitors in NSCLC [PDF]

Current Treatment Options in Oncology, 2014
Lung cancer is the leading cause of cancer-related mortality worldwide. Cytotoxic chemotherapy and tyrosine kinase inhibitors provide palliation and prolong survival, however, the median survival for patients with metastatic disease remains poor and more effective therapies are needed.
Douglas B, Johnson, Matthew J, Rioth, Leora, Horn   +2 more
openaire   +2 more sources

Intravenous immunoglobulin is safe and effective in controlling pre-existing paraneoplastic neuromuscular diseases in cancer patients treated with immune checkpoint inhibitors: two case reports and literature review

Frontiers in Oncology, 2023
Immune checkpoint inhibitors cause rare but potentially fatal neuromuscular complications, leading to a concern to use these agents in cancer patients with pre-existing autoimmune or inflammatory neuromuscular diseases.
Ge Xiong, Richard Benjamin Young, Helen Chow, Emanual Maverakis, Ricardo A. Maselli, David Paul Richman, Tianhong Li   +6 more
doaj   +1 more source

Immune Checkpoint Inhibitor-Associated Myocarditis

JACC: Case Reports, 2020
Immune checkpoint inhibitors (ICIs) can induce immunity-related adverse events. We demonstrate the clinical use of cardiac magnetic resonance and endomyocardial biopsy in the diagnosis and subsequent monitoring of ICI-associated myocarditis, suggesting ...
Grigorios Chatzantonis, MD, Georg Evers, MD, Claudia Meier, MD, Michael Bietenbeck, PhD, Anca Florian, MD, Karin Klingel, MD, Annalen Bleckmann, MD, Ali Yilmaz, MD   +7 more
doaj   +1 more source

Immune checkpoint inhibitor myocarditis: a systematic case study

Российский кардиологический журнал, 2020
Myocarditis is a life-threatening complication of immune checkpoint inhibitor therapy. Over the past ten years, drugs in this group have been used in the treatment of a wide range of hematological diseases and solid tumors.
E. A. Kushnareva, O. M. Moiseeva
doaj   +1 more source

Immune checkpoint inhibitor-associated sarcoidosis reaction [PDF]

Journal of Nephropathology, 2023
Immune checkpoint inhibitors (ICIs) constitute a class of drugs that stimulate the immune system to fight cancer cells. However, they can also induce immune-related adverse events (irAEs) in various organs, including the kidneys.
Parisa Keshtgar, Parisa Kaviani, Payam Peymani, Neda Kianpour, Samin Karamian   +4 more
doaj   +1 more source